HLA and killer immunoglobulin-like receptor genes as outcome predictors of hepatitis C virus-related hepatocellular carcinoma

Clinical Cancer Research

Volumn 19, Issue 19, 2013, Pages 5465-5473

  Cariani, Elisabetta ^a   Pilli, Massimo ^b   Zerbini, Alessandro ^c   Rota, Cristina ^a   Olivani, Andrea ^b   Zanelli, Paola ^b   Zanetti, Adele ^b   Trenti, Tommaso ^a   Ferrari, Carlo ^b   Missale, Gabriele ^b  

^a Nuovo Ospedale S Agostino   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c Rheumatology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENOTYPE; HEPATITIS C VIRUS; HLA BW4I80 GENE; HLA BW4T80 GENE; HLA C1 GENE; HLA C2 GENE; HLA GENE; HLA TYPING; HUMAN; KIR GENE; KIR2DL2 GENE; KIR2DL3 GENE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT RESPONSE; UPREGULATION;

AGED; CARCINOMA, HEPATOCELLULAR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, KIR; RECURRENCE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84886431345     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0986     Document Type: Article

References (36)

1. Moretta A, Tambussi G, Bottino C, Tripodi G, Merli A, Ciccone E, et al.A novel surface antigen expressed by a subset of human CD3 CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 1990;171:695-714.
2. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005;5:201-14.
3. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL.HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1-and NK2-specific natural killer cells. Proc Natl Acad Sci U S A 1993;90:12000-4.
4. Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 1995;3:801-9.
5. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008;180:3969-79.
6. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitopeofHLA-Bmolecule confers reactivitywith natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 1995;181: 1133-44.
7. Stewart CA, Laugier-Anfossi F, Vély F, Saulquin X, Riedmuller J, Tisserant A, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 2005;102:13224-9.
8. Jamil KM, Khakoo SI. KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol 2011;2011:298348.
9. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004;305:872-4.
10. Romero V, Azocar J, Z-uniga J, Clavijo OP, Terreros D, Gu X, et al. Interaction of NK inhibitory receptor genes with HLA-C andMHCclass II alleles in hepatitis C virus infection outcome. Mol Immunol 2008;45: 2429-36.
11. Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 2010;51:1168-75.
12. Dring MM, Morrison MH, McSharry BP, Guinan KJ, Hagan R, et al.Irish HCV Research Consortium Innate immune genes synergize to predict increased risk of chronic disease in hepatitisCvirus infection. Proc Natl Acad Sci U S A 2011;108:5736-41.
13. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010;138:1536-45.
14. Vidal-Castineira JR, López-Vázquez A, Díaz-Pena R, Alonso-Arias R, Martínez-Borra J, Pérez R, et al. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 2010;84:475-81.
15. Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in an European cohort: a cross-sectional study. PLoS Med 2011;8:e1001092.
16. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008;129: 428-37.
17. López-Vázquez A, Rodrigo L, Martínez-Borra J, Pérez R, Rodríguez M, Fdez-Morera JL, et al. Protective effect of theHLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 2005;192:162-5.
18. Alves LGT, Rajalingam R, Canavez F.Anovel real-timePCRmethod for KIR genotyping. Tissue Antigens 2008;73:188-91.
19. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011;39:D913-9.
20. Bontadini A, Testi M, Cuccia MC, Martinetti M, Carcassi C, Chiesa A, et al. Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population. J Transl Med 2006;4:44.
21. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994;180:1235-42.
22. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 2005;201:1069-75.
23. Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, et al.Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011;43: 455-8.
24. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006;18:151-8.
25. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. Increased regulatory T-cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39.
26. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140: 1501-12.
27. Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, Pelosi G, et al. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS ONE 2012;7:e32493.
28. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25:331-42.
29. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-13.
30. Brodin P, K?arre K, H?oglund P. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 2009;30:143-9.
31. Lanier LL. NK cell recognition. Ann Rev Immunol 2005;23:225-74.
32. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002;31:429-34.
33. Arnheim L, Dillner J, Sanjeevi CB. A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. Tissue Antigens 2005;65:252-9.
34. Butsch Kovacic M, Martin M, Gao X, Fuksenko T, Chen CJ, Cheng YJ, et al. Variation of the killer cell immunoglobulin-like receptors and HLAC genes in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2005;14:2673-7.
35. Pan N, Jiang W, Sun H, Miao F, Qiu J, Jin H, et al. KIR and HLA loci are associated with hepatocellular carcinoma development in patients with hepatitis B virus infection: a case-control study. PLoS ONE 2011;6:e25682.
36. Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr Opin Mol Ther 2010;12:724-33.